NAD+ Nasal Spray: Does It Work? What the Research Shows

NAD+ nasal sprays are sold with claims about brain energy, focus and anti-aging. The question that decides whether those claims mean anything is whether NAD+ sprayed into the nose reaches the blood or brain in people, and so far nobody has published an answer. This page sets out what exists for the nasal route, what exists for other routes, and what a buyer can and cannot check. It is a research reference, not medical advice.

What has been published on intranasal NAD+

A PubMed search on 6 November 2026 for intranasal NAD returned work in rats, mice and cultured cells. We found no study that measured NAD+ in human blood, spinal fluid or brain after a nasal dose, and no human trial of a nasal NAD+ product for any outcome. Absorption figures quoted by sellers do not come from a human study we could find.

What exists for other routes

A 2026 systematic review of 33 human intervention studies (28 randomised) found that oral nicotinamide riboside and nicotinamide mononucleotide consistently raised NAD-related metabolites in blood or cells, and were generally well tolerated over weeks to months. Effects on functional, metabolic and vascular outcomes were mixed and often null, and it found no eligible outcomes trials of intravenous or intramuscular NAD+ itself for anti-aging or wellness. Its conclusion: NAD+ augmentation shows clear biological activity, but clinical effectiveness for those aims remains inconclusive (Ageing Res Rev 2026).

The human data on NAD+ itself is intravenous. In a pilot, 8 healthy men received 750 mg over 6 hours and plasma NAD+ rose, with no adverse events during the infusion (Front Aging Neurosci 2019). Oral NAD+ does not effectively raise levels in plasma or tissue, according to a 2021 review, which is why supplements use precursors (Aging Dis 2021). The injection evidence is covered in the NAD+ injection guide.

Why the nasal route is promoted

The argument sellers make is that the nose gives a shortcut around the gut and a more direct path to the brain. The rat study above is the closest thing to support, and it is a stroke model with a dose given in an animal, not evidence of what a spray does in a healthy person. NAD+ is also a large charged molecule that does not cross cell membranes easily, and how an administered dose reaches cells is still argued over in the literature.

Regulatory status

NAD+ is not an FDA-approved drug: a Drugs@FDA search on 31 October 2026 returned no match for NAD, NADH or nicotinamide adenine dinucleotide. FDA's 2019 proposed rule on bulk drug substances for compounding did not add NAD to the list pharmacies may compound from (Federal Register, 5 September 2019), and the FDA compounding page, current as of 14 May 2026, shows no final rule. So a nasal NAD+ product is either a research chemical or a compounded product whose status depends on the pharmacy.

What to check before buying one

• The label should state NAD+ content per spray, not only a bottle total.
• Ask what batch testing exists. For research vials, a certificate of analysis with HPLC purity and identity on the same lot is the minimum; see how to read one.
• Treat any bioavailability percentage without a cited human study as marketing.
• Compare cost per milligram with injectable vials on NAD+ prices before assuming a spray is cheaper.

Related: NAD+ injection dosage chart and best place to buy NAD+.

Frequently asked questions

Does NAD+ nasal spray work?

There is no published human evidence either way. Studies of intranasal NAD or NAD+ exist in rats, mice and cultured cells, but we found none that measured NAD+ in human blood or brain after a nasal dose, or tested a spray in people for any outcome.

Is NAD+ nasal spray better than injections?

It cannot be shown to be better or worse, because there is no human absorption data for the spray. The human data on NAD+ itself is intravenous, and it measured blood levels, not benefits.

Is NAD+ nasal spray FDA approved?

No. NAD+ has no FDA-approved drug product, and FDA's 2019 proposed rule on compounding bulk substances did not add NAD to the list; the agency's compounding page, current as of 14 May 2026, shows no final rule.

Do NAD+ precursors like NMN and NR work better?

They have the human data. A 2026 systematic review found oral NR and NMN consistently raised NAD-related metabolites, but effects on health outcomes were mixed and often null.

Sources (checked 6 November 2026)

1. Ying et al, Intranasal administration with NAD+ profoundly decreases brain injury in a rat model of transient focal ischemia, Frontiers in Bioscience, 2007. Checked 6 November 2026.
2. Therapeutic effect of intranasal nicotinamide adenine dinucleotide in the restoration of olfactory dysfunction, Experimental and Molecular Medicine, 2026. Checked 6 November 2026.
3. Gallagher et al, NAD+ supplementation for anti-aging and wellness: a PRISMA-guided systematic review of preclinical and clinical evidence, Ageing Research Reviews, 2026. Checked 6 November 2026.
4. Grant et al, A pilot study investigating changes in the human plasma and urine NAD+ metabolome during a 6 hour intravenous infusion of NAD+, Frontiers in Aging Neuroscience, 2019. Checked 6 November 2026.
5. She et al, Pharmacology and potential implications of nicotinamide adenine dinucleotide precursors, Aging and Disease, 2021. Checked 6 November 2026.
6. Federal Register, 5 September 2019, Amendments to the List of Bulk Drug Substances That Can Be Used To Compound Drug Products in Accordance With Section 503A (proposed rule), entry on NAD. Checked 6 November 2026.
7. FDA, Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act (content current as of 14 May 2026). Checked 6 November 2026.

NAD+ is a coenzyme, not a peptide, and is listed alongside peptides by research vendors. Labels and trial records change; the leaflet in your box and your prescriber come first. Educational content, not medical advice.